Navigation Links
Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
Date:12/18/2007

SAN DIEGO, Dec. 18 /PRNewswire/ -- Ambrx Inc. today announced that it has entered into a global, strategic collaboration with Merck & Co. Inc. to develop a novel therapeutic protein with biological properties similar to Fibroblast Growth Factor 21 (FGF-21) for the treatment of type 2 diabetes and related metabolic disorders such as obesity.

The collaboration utilizes Ambrx's proprietary protein technology, ReCODE(TM), to develop a chemically modified and optimized drug candidate designed to have improved therapeutic properties over the native FGF-21 protein.

"We are pleased to enter into this agreement with Merck, a world leader in the metabolic diseases field with a proven track record in the rapid development and launch of diabetes medicines," said Stephen W. Kaldor, Ph.D., Ambrx's president and chief executive officer. "We are excited about the potential of our initial FGF-21 protein drug candidates, as they promise unique pharmacological efficacy in the treatment of diabetes, a disease of large and rapidly increasing prevalence."

"Molecules capable of mimicking the biological properties of the natural protein FGF-21 represent promising candidates for the treatment of metabolic disorders such as type 2 diabetes and obesity," said Luciano Rossetti, M.D., senior vice president and franchise head, Diabetes/Obesity and Cardiovascular Franchises at Merck. "Ambrx has developed several novel preclinical protein therapeutic candidates designed to provide enhanced therapeutic properties that may complement our portfolio of products for people with metabolic disorders."

The transaction includes an initial upfront payment in addition to committed R&D payments. Ambrx will also be eligible to receive future milestone payments associated with research, development and commercialization of a drug candidate resulting from the collaboration along with royalties on net sales. Ambrx also has the right to exercise an "end of Phase II" profit sharing option. Additional terms of the agreement were not disclosed. It is expected that this collaboration, in conjunction with three others announced this year, will preclude the necessity for Ambrx to raise additional equity capital for a number of years.

About Ambrx

Ambrx Inc. is a biopharmaceutical company focused on the discovery and development of first-in-class and best-in-class BioSuperior(TM), protein-based drugs. Using its technology, the company can overcome the performance limitations of high-value commercial proteins by improving their efficacy, safety and ease of use. Ambrx's core ReCODE(TM) technology enables the precise, site-specific substitution of a novel amino acid within a protein. This allows the conjugation of proteins with additional molecules that can serve to modulate their pharmacokinetic profile or biological function. Ambrx's ReCODE(TM) technology is applicable to multiple protein products across numerous therapeutic areas. Ambrx has successfully and rapidly applied its innovative technology platform to advance into the clinic with ARX201, its first proprietary molecule, and is building a broad pipeline of additional product opportunities. For additional information, call 858.875.2400 or visit http://www.ambrx.com.


'/>"/>
SOURCE Ambrx Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Cepheid Announces Termination of Contract With the Centers for Disease Control and Prevention to Develop Rapid Point of Care Test for Avian Influenza
5. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers
6. Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
10. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
11. Cleveland Clinic Study Shows the Diabetes Drug Pioglitazone Reduces Risk of Death, Heart Attack and Stroke, but Increases Risk of Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... and PUNE, India , March 24, 2017 ... Bone Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone ... reach $724 million by 2022, growing at a CAGR of 3.6% during the ... ... Allied Market Research Logo ...
(Date:3/24/2017)... Research and Markets has announced the addition of ... report to their offering. ... Pain Management in the U.S.: Consumer ... pain, emphasizing consumer survey analysis, including trends over time. The ... have selected illnesses/conditions strongly associated with physical pain and pain ...
(Date:3/24/2017)... FinancialBuzz.com News Commentary  ... According to new data ... research, the legal cannabis market is projected to continue to ... signals from the current presidential administration. The report created by ... drivers of growth in this industry are the passage and ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF Orthopaedic Center ... Houston Area. The new location is located at 2255 E. Mossy Oaks Rd., Suite ... This newest location will provide patients living in the north Houston area (The Woodlands, ...
(Date:3/23/2017)... ... 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on April 22 ... be an educational and exciting program providing busy clinicians and allied healthcare practitioners ... , Oklahoma is in a healthcare crisis. The state ranks 46th in America ...
(Date:3/23/2017)... ... 23, 2017 , ... 82% of adults are unaware of the dangers that infectious bacteria play ... the minimum two times a day that dentists recommend. The ramifications of improper oral upkeep ... school and adults missing 164 million hours of work each year due to dental issues. ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... SmartBen NOW, an innovative mobile app and centralized benefits dashboard solving one of ... information securely from multiple locations. For the first time, employees can access up-to-date ...
Breaking Medicine News(10 mins):